From Name:
From Email:
To Name:
To Email:

Optional Message:

Microvascular invasion as a predictor of response to treatment with sorafenib and transarterial chemoembolization for recurrent intermediate-stage hepatocellular carcinoma

from Radiology

Patients with recurrent intermediate-stage hepatocellular carcinoma and microvascular invasion–positive status benefit from longer survival times by using a combined treatment of sorafenib with transarterial chemoembolization (TACE) compared with TACE alone. The evidence of combining sorafenib with transarterial chemoembolization (TACE) for intermediate-stage recurrent hepatocellular carcinoma (HCC) is limited. Patient responses to this treatment varied because of the heterogeneous nature of intermediate-stage recurrent HCC, making it important to identify patients who are most likely to benefit from this combination therapy. more

Powered by MultiBriefs
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063